{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:39:29Z","timestamp":1792172369201,"version":"4.4.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have transformed oncology but predispose patients to immune-related adverse events. Immune-mediated cystitis represents a rare yet clinically significant urological complication requiring enhanced surveillance. This studies characterizes the pharmacovigilance profile of immune-mediated cystitis across ICI classes using real-world post-market surveillance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods:<\/jats:title>\n                    <jats:p>\n                      This disproportionality analysis utilized the FDA Adverse Event Reporting System (FAERS) database, encompassing reports from Q4 2003 through Q3 2025. Fourteen ICIs were evaluated across four mechanistic classes: PD-1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20097), PD-L1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20094), CTLA-4 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20092), and LAG-3 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091) inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 14,104,743 adverse event reports, 69 cases of immune-mediated cystitis were identified. PD-1 inhibitors demonstrated the strongest signals: pembrolizumab (ROR 241.59; 95% CI 149.40\u2013390.68;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200928), nivolumab (ROR 118.56; 95% CI 68.56\u2013205.02;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200917), toripalimab (ROR 454.65;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20092), and tislelizumab (ROR 266.31;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20093). Ipilimumab exhibited robust disproportionality (ROR 297.28; 95% CI 167.73\u2013526.89;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200915). PD-L1 inhibitors showed minimal signals with isolated cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Immune-mediated cystitis demonstrates strongest association with PD-1 and CTLA-4 inhibitors, warranting enhanced clinical surveillance, prompt recognition, and evidence-based management protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603261446420","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:19:31Z","timestamp":1777544371000},"page":"396-401","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between immune-mediated cystitis and PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: A pharmacovigilance study from the FAERS database"],"prefix":"10.1177","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4080-3030","authenticated-orcid":false,"given":"Connor","family":"Frey","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Sharma P Goswami S Raychaudhuri D et al. Immune checkpoint therapy-current perspectives and future directions. Cells 2023; 186(8): 1652\u20131669. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Wan G Chen W Khattab S et al. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. Lancet Oncol 2024; 25(8): 1053\u20131069. https:\/\/doi.org\/10.1016\/S1470-2045(24)00278-X","DOI":"10.1016\/S1470-2045(24)00278-X"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Ramos-Casals M Brahmer JR Callahan MK et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020; 6(1): 38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","DOI":"10.1038\/s41572-020-0160-6"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Frey C Etminan M. Adverse events of PD-1 PD-L1 CTLA-4 and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database. Antibodies 2024; 13(3): 59. https:\/\/doi.org\/10.3390\/antib13030059","DOI":"10.3390\/antib13030059"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Yan Y Dou Q Wu X et al. Immune checkpoint inhibitor-induced ureteritis and cystitis in patients with lung cancer and uterine malignancies: a case series and literature review. J Immunother 2026; 49: 108\u2013114. https:\/\/doi.org\/10.1097\/CJI.0000000000000581","DOI":"10.1097\/CJI.0000000000000581"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Xiao J Tang S Xia Z et al. Clinical presentation of PD-1\/PD-L1 immune checkpoint inhibitors induced cystitis. Investig New Drugs 2025; 43(4): 770\u2013779. https:\/\/doi.org\/10.1007\/s10637-025-01563-2","DOI":"10.1007\/s10637-025-01563-2"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Fan Y Zhao J Mi Y et al. Recurrent cystitis associated with 2 programmed death 1 inhibitors: a rare case report and literature review. J Immunother 2023; 46(9): 341\u2013345. https:\/\/doi.org\/10.1097\/CJI.0000000000000484","DOI":"10.1097\/CJI.0000000000000484"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Zhu S Bian L Lv J et al. A case report of non-bacterial cystitis caused by immune checkpoint inhibitors. Front Immunol 2021; 12: 788629. https:\/\/doi.org\/10.3389\/fimmu.2021.788629","DOI":"10.3389\/fimmu.2021.788629"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Di C Yu T Ni L. Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report. Front Immunol 2024; 15: 1423123. https:\/\/doi.org\/10.3389\/fimmu.2024.1423123","DOI":"10.3389\/fimmu.2024.1423123"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Li J Yu YF Qi XW et al. Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: case report and literature review. Front Immunol 2022; 13: 1051577. https:\/\/doi.org\/10.3389\/fimmu.2022.1051577","DOI":"10.3389\/fimmu.2022.1051577"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Gokhale P Akosah A Villa Zapata L. Immune-related adverse events associated with immune checkpoint inhibitor therapy in bladder cancer patients: a systematic review and meta-analysis. Urol Oncol 2026; 44: 79\u201391. https:\/\/doi.org\/10.1016\/j.urolonc.2025.11.010","DOI":"10.1016\/j.urolonc.2025.11.010"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Yuan Y Lou L Zhu S et al. Immunotherapy-related cystitis induced by nivolumab: a case report and review of the literature. Urol Case Rep 2025; 62: 103132. https:\/\/doi.org\/10.1016\/j.eucr.2025.103132","DOI":"10.1016\/j.eucr.2025.103132"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Kim YJ Lee M Kim EH et al. Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: a nationwide retrospective cohort study. Cancer Lett 2024; 596: 216998. https:\/\/doi.org\/10.1016\/j.canlet.2024.216998","DOI":"10.1016\/j.canlet.2024.216998"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Alhusari L Abdallah M Nwanwene K et al. Acute non-infectious cystitis secondary to immune-related adverse events in a patient receiving pembrolizumab for treatment of non-small cell lung cancer: a case report. Cureus 2024; (3): 16. https:\/\/doi.org\/10.7759\/cureus.55666","DOI":"10.7759\/cureus.55666"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Zhang P Yin C Yang M. Case reports of immune-related cystitis and the antibody combination hypothesis. Immunotherapy 2024; 16(16\u201317): 1039\u20131047. https:\/\/doi.org\/10.1080\/1750743X.2024.2389761","DOI":"10.1080\/1750743X.2024.2389761"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Li X Ao M Tian S et al. Prolonged survival of thoracic SMARCA4-deficient undifferentiated tumor with immune-related cystitis: a case report and literature review. Ther Adv Respir Dis 2025; 19: 17534666251385689. https:\/\/doi.org\/10.1177\/17534666251385689","DOI":"10.1177\/17534666251385689"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Ueki Y Matsuki M Kubo T et al. Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: an unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma. IJU Case Rep 2020; 3(6): 266\u2013269. https:\/\/doi.org\/10.1002\/iju5.12211","DOI":"10.1002\/iju5.12211"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Tu L Ye Y Tang X et al. Case report: a case of sintilimab-induced cystitis\/ureteritis and review of sintilimab-related adverse events. Front Oncol 2021; 11: 757069. https:\/\/doi.org\/10.3389\/fonc.2021.757069","DOI":"10.3389\/fonc.2021.757069"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Yajima S Nakanishi Y Matsumoto S et al. Improvement of urinary symptoms after bladder biopsy: a case of pathologically proven allergy-related cystitis during administration of nivolumab. IJU Case Rep 2021; 4(4): 213\u2013215. https:\/\/doi.org\/10.1002\/iju5.12286","DOI":"10.1002\/iju5.12286"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Xu C Chen YP Du XJ et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018; 363: k4226. https:\/\/doi.org\/10.1136\/bmj.k4226","DOI":"10.1136\/bmj.k4226"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Chen W Yoshida S Miura N et al. Effectiveness and safety of pembrolizumab nivolumab and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison. Front Oncol 2025; 14: 1527540. https:\/\/doi.org\/10.3389\/fonc.2024.1527540","DOI":"10.3389\/fonc.2024.1527540"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Shen X Huang S Xiao H et al. Efficacy and safety of PD-1\/PD-L1 plus CTLA-4 antibodies \u00b1 other therapies in lung cancer: a systematic review and meta-analysis. Eur J Hosp Pharm 2023; 30(1): 3\u20138. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002803","DOI":"10.1136\/ejhpharm-2021-002803"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Schneider S Alezra E Yacoub M et al. Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma. Melanoma Res 2021; 31(5): 487\u2013489. https:\/\/doi.org\/10.1097\/CMR.0000000000000765","DOI":"10.1097\/CMR.0000000000000765"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Zhou Q Qin Z Yan P et al. Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis\/cystitis and review of the literature. Front Immunol 2023; 14: 1226993. https:\/\/doi.org\/10.3389\/fimmu.2023.1226993","DOI":"10.3389\/fimmu.2023.1226993"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Ji J Lai CH Zhang X et al. Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis\/cystitis treated by ureteral stent and review of the literature. Front Immunol 2024; 15: 1501415. https:\/\/doi.org\/10.3389\/fimmu.2024.1501415","DOI":"10.3389\/fimmu.2024.1501415"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Shimatani K Yoshimoto T Doi Y et al. Two cases of nonbacterial cystitis associated with nivolumab the anti-programmed-death-receptor-1 inhibitor. Urol Case Rep 2018; 17: 97\u201399. https:\/\/doi.org\/10.1016\/j.eucr.2017.12.006","DOI":"10.1016\/j.eucr.2017.12.006"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Fukunaga H Sumii K Kawamura S et al. A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer which was successfully treated with infliximab. IJU Case Rep 2022; 5(6): 521\u2013523. https:\/\/doi.org\/10.1002\/iju5.12532","DOI":"10.1002\/iju5.12532"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Dolladille C Ederhy S Sassier M et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 2020; 6(6): 865\u2013871. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0726","DOI":"10.1001\/jamaoncol.2020.0726"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Delyon J Louren\u00e7o N Vu LT et al. Recurrence of immune-mediated colitis upon immune checkpoint inhibitor resumption: does time matter? J Clin Oncol 2019; 37(36): 3563\u20133564. https:\/\/doi.org\/10.1200\/JCO.19.01891","DOI":"10.1200\/JCO.19.01891"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261446420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261446420","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261446420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:33:02Z","timestamp":1789619582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261446420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/03915603261446420"],"URL":"https:\/\/doi.org\/10.1177\/03915603261446420","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}